Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) EBITDA Margin: 2010-2025

Historic EBITDA Margin for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Sep 2025 value amounting to 6.71%.

  • Arrowhead Pharmaceuticals' EBITDA Margin fell 113760.00% to 6.71% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.83%, marking a year-over-year decrease of 256389.00%. This contributed to the annual value of 3.83% for FY2025, which is 1694895.00% up from last year.
  • According to the latest figures from Q3 2025, Arrowhead Pharmaceuticals' EBITDA Margin is 6.71%, which was up 101.05% from -639.91% recorded in Q2 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' EBITDA Margin peaked at 3,413.21% during Q2 2024, and registered a low of -7,033.24% during Q4 2024.
  • Over the past 3 years, Arrowhead Pharmaceuticals' median EBITDA Margin value was 6.71% (recorded in 2025), while the average stood at -580.02%.
  • In the last 5 years, Arrowhead Pharmaceuticals' EBITDA Margin surged by 407,169bps in 2024 and then crashed by 405,313bps in 2025.
  • Quarterly analysis of 5 years shows Arrowhead Pharmaceuticals' EBITDA Margin stood at -229.28% in 2021, then skyrocketed by 16,223bps to -67.04% in 2022, then tumbled by 368,990bps to -3,756.94% in 2023, then crashed by 327,630bps to -7,033.24% in 2024, then tumbled by 113,760bps to 6.71% in 2025.
  • Its EBITDA Margin stands at 6.71% for Q3 2025, versus -639.91% for Q2 2025 and 67.83% for Q1 2025.